Clinical trials from CRA s point of view
|
|
- Cathleen Johnson
- 6 years ago
- Views:
Transcription
1 Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO
2 REGULATION of CLINICAL TRIALS World Medical Association Declaration of Helsinki (est. 1964, last updated 2004) ICH-GCP guidelines EU directive 2001/20/EC EU directive 2003/94/EC EU directive 2005/28/EC Country specific regulations
3 REGULATION of CLINICAL TRIALS World Medical Association Declaration of Helsinki In medical research on human subjects, consideration to the well-being of the human subject should take precedence over the interests of science and society. It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subject. The subjects must be volunteers and informed participation in the research project.
4 REGULATION of CLINICAL TRIALS ICH-GCP guidelines A unified standard for EU, Japan and US Covers all area of clinical trials Allows the Sponsor to delegate number of tasks to CRO Introduces monitor (CTM/CRA) role in the trials
5 REGULATION of CLINICAL TRIALS EU directive 2001/20/EC Introducing the law, regulations and administrative provisions of the Member States relating to the implementation on good clinical practice in the conduct of clinical trials on medicinal products for human use. Adopted by all 25 EU countries on 1 st of May Standardisation of processes and timelines in all EU countries.
6 REGULATION of CLINICAL TRIALS EU directive 2003/94/EC Introducing the the principles and guidelines of good manufacturing practices in respect of medicinal products for human use and investigational medicinal products for human use. Instruction for whole process of manufacturing and distribution of all medicinal products. Annex 13 describes GMP guidelines for IMP
7 REGULATION of CLINICAL TRIALS EU directive 2005/28/EC Introducing the the principles and detailed guidelines for good clinical practice as regards investigational medicine products for human use, as well the requirements for authorisation of the manufacturing or importation of such products. Extension of EU directive 2001/20/EC over import authorisation, archiving and inspection procedures.
8 REGULATION of CLINICAL TRIALS Country specific regulations Each EU country has own specific regulation UK: EC and RA submission in parallel Germany: EC and RA submission in parallel Poland: RA submission is done after EC submission
9 CLINICAL TRIALS in STEPS idea protocol feasibility PSV Site selection EC/RA SIV IMP realise recruitment MV(s) Data collection Database entry Database lock Statistical analysis Final report? CRA CTM
10 CLINICAL TRIALS in STEPS idea new medical substance new formulation new indication additional data request by RA protocol study objective study design study procedure and assessments
11 CLINICAL TRIALS in STEPS feasibility can we do the trails? patient population protocol feedback further suggestion
12 CLINICAL TRIALS in STEPS PSV PRE-STUDY VISIT study/protocol review investigator discussion site-specific issue document collection
13 CLINICAL TRIALS in STEPS Site selection site eligibility assessment based on PSV EC/RA EC (Ethics Committee) and RA (Regulatory Authority) approval is legal requirements essential part of critical documents requires for drug realise
14 CLINICAL TRIALS in STEPS SIV SITE INITIATION VISIT meeting team members explanation of study design/protocol requirements background of study medication how to record data (medical notes, CRF) investigator site file pharmacy file study supplies/procedures
15 CLINICAL TRIALS in STEPS IMP realise recruitment as soon as critical document pack is approved IMP (Investigational Medicine product) can be realised Pharmacy confirms IMP shipment patient recruitment is open
16 CLINICAL TRIALS in STEPS MV(s) SITE MONITORING VISIT to ensure that patient was properly consented to monitor patient safety to ensure that study is being conducted with ICH-GCP, the protocol and any other EC/RA requirements to ensure that data collected on CRF (Case Report Form) are complete and verifiable to perform IMP accountability
17 CLINICAL TRIALS in STEPS MV(s) INFORMED CONSENT A process by which a subject voluntary confirms his/her willingness to participate in a particular trials, after having been informed of all the aspects of the trails that are relevant to the subject s decision to participate. Informed consent is documented by means of a written, signed and dated inform consent form, both by a patient and a physician.
18 CLINICAL TRIALS in STEPS MV(s) PATIENT SAFETY Patient safety is priority # 1 in the clinical trials! Adverse Event(s) Pregnancy Precautions IMP handling, dispensing and administration
19 AE (adverse event) What is an AE? Any untoward medical occurrence in patient or a trail subject, administered a pharmaceutical product, which does not necessarily have to have a casual relationship with this treatment. New/worsened symptoms Abnormal medical exam Laboratory abnormalities A E Any pregnancy Accidents Drug dependency/abuse Under-/over- dose of IMP
20 What is a SAE? SAE - serious adverse event Seriousness criteria Results in death Is life-threatening A E Requires/prolongs hospitalisation Birth/congenital abnormalities Persistent disability/incapacity Other medical condition SAE
21 When AE is SAE/AR/SAR/SSAR/SUSAR? A E Serious? YES! Related to IMP? YES! AR Serious? YES! SSAR SAE Related to IMP? YES! SAR First SAR? NO! YES! SUSAR
22 PREGNANCY PRECAUSION Pregnancy precaution are mandatory! F M contraception during the whole study pregnancy tests during whole study (females) Pregnancy F M Study discontinuatio n Pregnancy report Follow up until Any abnormalities SAE Delivery
23 IMP HANDLING Is IMP storage acceptable? Has IMP expired? Has correct IMP been given to patient? Has correct dose been given to patient? What is patient compliance? Have all steps been properly recorded?
24 CLINICAL TRIALS in STEPS Data collection Database entry Database lock Statistical analysis Final report? site close out visit next phase drug licensing
25 ONCOLOGY TRIALS 1 placeb o cytostati c No phase one Special precautions with IMP handling No placebo group - always comparator
26 CONCLUSIONS Each step in clinical trials is well-defined Patient safety is priority #1 Monitor role is essential part of trials CRA is involved in many steps of trials CRA is the middle link between a Sponsor and patients Oncology trials have different design
27 QUESTIONS?
Good Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationRegulatory and ethical requirements in medical devices studies. France
Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationRecording, Managing and Reporting Adverse Events in the UK
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationClinical Research & ICH GCP E6(R2) (Basic / Refresher Training):
Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationSAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA
SAE Reporting Timelines, Causality Assessment And Compensation Pawandeep Kaur Associate Medical Director CDSA Objective Background Important definitions SAE Reporting Timelines Causality Assessment Compensation
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationWorkstream 6: Pharmacovigilance
Workstream 6: Pharmacovigilance 1.0 Introduction... 2 1.1 Background... 2 1.2 Definitions... 3 2.0 Definition of Sponsor for Pharmacovigilance... 4 3.0 General Considerations: Risk Adapted Approaches to
More informationCompetent federal higher authority ("Bundesoberbehörde- BOB")
Nutrition/InterventionaI - GERMANY Competent authority Contact Details Contact Name 1 Competent federal higher authority ("Bundesoberbehörde- BOB") Contact Name 2 Federal Institute for Drugs and Medical
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationGUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
More informationRegulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for
Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111
More informationImplementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.
Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G. History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd History (2) 10 basic ethical
More informationData Quality and Integrity: From Clinical Monitoring to Marketing Approval
Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationClinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski
Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Agenda Why are clinical trials conducted? History Guidelines and Regulations When are trials conducted? Requirements
More informationII. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD
II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD Selected Topics Definitions Communication & Interaction Phase I Clinical Trials Safety
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationStandard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research
Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research September 2007 Version 1.0 Prepared by Nucleus Network on behalf of VMIA Introduction to the
More informationPharmacovigilance Playbook (Part 1 of 2)
PHARMACOVIGILANCE AND RISK MANAGEMENT Pharmacovigilance Playbook (Part 1 of 2) Compiled By: Dr. Mufti Suhail Sayeed James Lind Institute www.jliedu.com www.jli.edu.in James Lind Institute www.jliedu.com
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationSafety monitoring and reporting in clinical trials involving therapeutic goods
Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 Publication Details Publication title: Guidance:. Published: November 2016 Publisher: National Health and Medical
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationDefinitions and Acronyms
Definitions and Acronyms 510(k) A particular FDA Class For Medical Devices AE Adverse Event CFR Code of Federal Regulations CMS United States Center/College for Medicare and Medicaid Services CRA Clinical
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationImplementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials
Implementing the Directive - from the Swedish Perspective Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Previous system in Sweden CA (LVFS 1996:17) Approval of applications
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationREQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:
Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE
More informationSINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)
SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the
More informationThe Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget
The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive
More informationStandard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary
Standard Operating Procedures for Clinical Research Personnel Part 16 Wendy Bohaychuk and Graham Ball GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO Summary This is the 16th in a
More informationEthics and Clinical trials EU approach
Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationEuropean Medicines Agency Perspective
European Medicines Agency Perspective WMA Workshop on revision of DoH, 4-6 Dec 2012, Capetown, South Africa. Presented by: Fergus Sweeney, PhD Head of Sector, Compliance and Inspection, European Medicines
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationSERIOUS ADVERSE EVENTS
EVENTS Introduction Timely reporting of Serious Adverse Events (SAEs) is required by regulations of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Such reporting is not
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationApplication form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE
Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationDeveloping a European First-in-Human Study: Three Key Decisions
Developing a European First-in-Human Study: Three Key Decisions By Nicole Feist, BA Clinical A key step in the translational medicine benchtop to bedside process model is the move from research and preclinical
More informationINTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH) ICH HARMONISED GUIDELINE INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE
More informationWorld Medical Association Declaration of Helsinki
World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended by the
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.
ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationCentral Drugs Standard Control Organization Dte.GHS, Ministry of Health and Family Welfare, Gov ernment of India
Central Drugs Standard Control Organization Dte.GHS, Ministry of Health and Family Welfare, Gov ernment of India Home Site Map Archive Feedback Downloads Contact FOREWORD Good Clinical Practices For Clinical
More informationThe Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationGCP Inspections: Legal Basis
Systems Inspections Workshop 24 April 2013 Dr Simone Ferbitz PhD, Eidg. Dipl. Pharm. ETH GCP Inspector, Swissmedic Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern www.swissmedic.ch
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationMinistry of Health Pharmaceutical Administration Jerusalem. Guidelines for Clinical Trials in Human Subjects
Ministry of Health Pharmaceutical Administration Jerusalem Guidelines for Clinical Trials in Human Subjects In accordance with the Public Health Regulations (Clinical Trials in Human Subjects) 1980 2006
More informationSimonetta Viviani, MD BIO-VIPE Consulting Limited, Hong Kong
Simonetta Viviani, MD BIO-VIPE Consulting Limited, Hong Kong DCVMN Clinical Development & Pharmacovigilance Training 17-21 July 2016, Bali, Indonesia Pratical tips on how to write a protocol Write the
More informationICH Topic E 6 Guideline for Good Clinical Practice NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) *
The European Agency for the Evaluation of Medicinal Products ICH Topic E 6 Guideline for Good Clinical Practice Step 5, Consolidated Guideline 1.5.96 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95)
More informationWMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Download the PDF file Adopted by the 18 th WMA General Assembly, Helsinki, Finland, June 1964 and amended
More informationRegulations & Guidelines Specific to Ethics Schedule Y & CDSCO-GCP
Regulations & Guidelines Specific to Ethics Schedule Y & CDSCO-GCP Dr. K. Bangarurajan M Pharm, PhD Deputy Drugs Controller (India) CDSCO West Zone Outline Licensing Authority India - Clinical Trial: CDSCO
More informationEU Regulation Review: challenges and opportunities for industry
EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More information